Document is current
Any future updates will be listed below
-
Authors
Deodhar, Atul
Maculaitis, Martine C.
Kopenhafer, Lewis
Beusterien, Kathleen
Ling, You-Li
Hauber, Brett
Cappelleri, Joseph C.
Yndestad, Arne
Phillips, Lawrence rick
Zayed, Mostafa
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 19 December 2025
First Online: 20 January 2026
Declarations
:
: Atul Deodhar: Consulting and Advisory Boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, and UCB; Research Grants: Bristol Myers Squibb, Eli Lilly, J&J, MoonLake, Novartis, Pfizer, and UCB. You-Li Ling, Brett Hauber, Joseph C. Cappelleri, Arne Yndestad, and Mostafa Zayed: Employed by and owns stock/stock options in Pfizer. Lawrence Rick Phillips: No conflicts of interest to disclose. Martine C. Maculaitis, Lewis Kopenhafer, and Kathleen Beusterien: Employed by Oracle Life Sciences, which provides consulting services to Pfizer.
: The study protocol, qualitative interview discussion guide, informed consent statement, and quantitative survey were reviewed by Sterling IRB (Atlanta, Georgia, US), and an exemption determination was granted on July 26, 2022 (IRB ID #: 10267-MMaculaitis). To participate in either the qualitative interviews or the quantitative survey, patients provided their informed consent verbally or electronically, respectively. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.
